Postmenopausal osteoporosis is a metabolic disease associated with estrogen deficiency. The results of numerous studies have revealed the positive correlation between iron accumulation and postmenopausal osteoporotic status. Although the results of previous studies have indicated that estrogen or iron alone have an effect on bone metabolism, their combined effects are not well defined. Using an in vivo mouse model, we found that bone mass was minimally affected by an excess of iron in the presence of estrogen. Once the source of estrogen was removed (ovariectomy), iron accumulation significantly decreased bone mass. These effects were accompanied by fluctuations in the level of oxidative stress. To determine whether these effects were related to bone formation or bone resorption, primary osteoblasts (OBs), RAW264.7 cells, and bone-marrow-derived macrophages were used for in vitro experiments. We found that iron accumulation did inhibit the activity of OBs. However, estrogen had little effect on this inhibition. In contrast, iron promoted osteoclast differentiation through the production of reactive oxygen species. Estrogen, a powerful reactive oxygen scavenger, suppressed this effect in osteoclasts. Our data provided direct evidence that iron affected the bone mass only in the absence of estrogen. The inhibitory effect of estrogen on iron-induced osteopenia was particularly relevant to bone resorption rather than bone formation.
Introduction
Primary type I osteoporosis, also known as postmenopausal osteoporosis (PMO), is a bone disease associated with reduced bone mineral density, disordered bone architecture and increased fragility (Chinese Orthopaedic Association 2009, Van den Bergh et al. 2012) . Osteoporosis occurs when the bone mass decreases more rapidly than the body can replace it. Approximately 50% of women over 50 years of age suffer from osteoporosis, resulting in staggering financial costs for the USA (Ross 1996 , Ray et al. 1997 . Estrogen deficiency is regarded as the main causative factor in PMO. Withdrawal of estrogen or estrogen deficiency stimulates bone resorption by 90%, while increasing bone formation by 45%, as measured using biochemical markers (Yang et al. 2011 ).
This phenomenon, bone resorption outpacing bone formation, cannot be explained by estrogen deficiency alone (Huang et al. 2013) . Therefore, we examined whether estrogen shortage is the sole factor in the development of PMO or if other risk factors are involved.
Iron overload has recently been linked to abnormalities in bone metabolism, including osteopenia, osteoporosis, and osteomalacia (Matsushima et al. 2001 , Guggenbuhl et al. 2005 . Osteoporosis occurs frequently in disorders associated with an excess of iron, such as thalassemia and hereditary hemochromatosis (Mahachoklertwattana et al. 2003 , Vogiatzi et al. 2006 . Most importantly, iron accumulation, a recently observed clinical phenomenon in postmenopausal women, might be involved in the pathogenesis of PMO (Kim et al. 2012) . Menses is a critical pathway of iron excretion while menopause is a natural aging process that occurs as a woman passes from the reproductive to the non-reproductive years (Milman & Kirchhoff 1992 , Riggs et al. 2002 . Because of physiological amenorrhea, postmenopausal women experience an excess of iron. Although this iron status is considered to be within the normal physiological range, PMO has been linked to increased iron storage, a normal but not necessarily healthy process (Kim et al. 2013) . Although there was no report of the relationship between iron and osteocytes, inhibition of osteoblastogenesis and stimulation of osteoclastogenesis caused by iron had been reported (Jia et al. 2012 , He et al. 2013 ) and reactive oxygen species (ROS) were involved in ironinduced osteopenia . ROS attenuate osteoblastogenesis, decrease osteoblast/osteocyte lifespan, and are required for osteoclast generation, function, and survival . Estrogen has been shown to increase markers of oxidative stress in bone . We propose the hypothesis that estrogen deficiency and increased iron levels are the main and secondary risk factors for PMO respectively. We speculate that iron accumulation aggravates PMO in the absence of estrogen. Furthermore, this deterioration would be suppressed if estrogen is restored using hormone replacement therapy.
In previous work, we established a male mouse model to observe the influence of iron on oxidative stress and bone resorption in vivo (Jia et al. 2012) . In addition, we treated a murine macrophage cell line, RAW264.7 with ferric ions to test their activity (Jia et al. 2012) . We found that iron promotes osteoclast differentiation and bone resorption. Using the fluorescent probe dichlorodihydro-fluorescein diacetate (DCFH-DA), we examined oxidative stress as the underlying cause of iron-induced enhanced osteoclast function and increased osteoclast differentiation. Our results confirmed that these effects were regulated by the level of reactive oxidative species (ROS) .
To examine the combined action of estrogen and iron on bone metabolism, especially the role of iron in PMO, we established an ovariectomized, iron-treated female mouse model. We performed experiments on primary osteoblasts (OBs), bone-marrow-derived macrophages (BMMs), and RAW264.7 cells to elucidate the mechanism underlying the development of PMO. We propose the hypothesis that the NF-kB signaling pathway may be involved in this development. This pathway is activated by virtually all stimuli that affect NF-kB including the receptor activator of NF-kB ligand (RANKL), the master osteoclastogenic cytokine and ROS (Ha et al. 2004 , Lee et al. 2005 . Free iron produces ROS through Fenton reactions, and estrogen is a well characterized antioxidant (Kim et al. 2006 , Nakrst et al. 2011 . Our analysis of the combined action of estrogen and iron may further our understanding of PMO pathogenesis.
Materials and methods

Animal experiments
All animal experiments were approved by the animal care committee of Soochow University. Two-month-old ICR female mice were divided into four groups (nZ6/group). Two groups of mice were bilaterally ovariectomized and received intraperitoneal injections of normal saline (OVX) or 40 mg/kg ferric ammonium citrate (FAC) (FCOVX) three times a week for 2 months. The feed was decreased after ovariectomy for weight control. The Control (Con) and F groups, considered as sham operation groups, received identical normal saline and FAC treatments, but their ovaries were not excised. All mice were killed 2 days after the last treatment, and the body weight of all mice was measured.
Blood was collected from the dead mice and then centrifuged at 1000 g for 10 min in order to acquire the serum. Aliquots of serum were stored at K80 8C for future analysis. BMMs were immediately extracted from one of the two femurs. The other femur from each mouse was scanned using micro-CT. The femurs and livers were then fixed in 10% buffered formalin at 4 8C for Prussian blue staining.
Culture of OBs
Primary OBs derived from the calvaria of 1-day-old ICR mice were obtained as described previously (Suda et al. 1997) . OBs were maintained in phenol-red-free a-MEM (Gibco) supplemented with 10% fetal bovine serum (FBS) (HyClone, Logan, UT, USA), 100 units/ml penicillin and 100 mg/ml streptomycin in a humidified atmosphere of 5% CO 2 at 37 8C. The medium was replaced every 2 days. After reaching 70% confluence, the cells were detached using 0.05% trypsin and re-plated in either 55-cm 2 dishes or 12-well plates (3.8 cm 2 wells) at a density of 1!10 4 cells/cm 2 . The medium was replaced with serum-free medium containing 0 nM or 10 nM estradiol (E 2 ) (Krum et al. 2008) . Then deionized water or 10 mM FAC were used as intervention reagents (Messer et al. 2009 ). Throughout the culture period, 25 mg/ml ascorbic acid, 10 mM sodium b-glycerolphosphate, and 100 nM dexamethasone were supplied to the cells.
Culture of osteoclasts
Murine RAW264.7 macrophage cells were plated in 55-cm 2 dishes or in 96-well plates at 3!10 3 cells/well. RAW264.7 cells were cultured in phenol-red-free a-MEM/10% FBS containing 100 ng/ml RANKL (PeproTech, Rocky Hill, NJ, USA) for 4 days at 37 8C and 5% CO 2 . Serum-free medium containing deionized water, E 2 , or FAC was supplied to cells during the last 2 days of culture. The method of intervention was the same as for the experiments on OBs. BMMs were isolated from the femurs by flushing the bone marrow cavity with phenol-red-free a-MEM. Isolated cells were then centrifuged. The medium was replaced with ammonium-chloride-potassium buffer (pH 7.4, 0.1 mM NH 4 Cl, 0.1 mM EDTA, and 1 mM K 2 CO 3 ) for 30 s at room temperature to remove the red blood cells. Cells were cultured for 24 h in a-MEM/10%FBS. To generate osteoclast precursors, the non-adherent cells were collected and then cultured for 3 days in the presence of 30 ng/ml of macrophage colony-stimulating factor (M-CSF; PeproTech). The floating cells were discarded and adherent cells were considered to be BMMs. BMMs were cultured in a-MEM containing 30 ng/ml M-CSF and 50 ng/ml RANKL for 5 days.
Cell proliferation assay
Cell proliferation was analyzed using the Cell Counting kit 8 (Dojindo, Tokyo, Japan). RAW264.7 cells were detached and seeded into 96-well plates at a density of 3!10 3 cells/well.
After 24 h, cells were treated with FAC at various concentrations (12, 25, 50, 100, and 200 mM, 100 ml/well) or E 2 (1, 10, 10
, and 10 4 nM, 100 ml/well) and they were then incubated for another 24 h. The optical density (OD) of each group was measured at 450 nm using a BioTek microplate reader.
Alkaline phosphatase, alizarin red staining and alkaline phosphatase activity
OBs were treated with FAC and E 2 for 3 days and were then stained using alkaline phosphatase (ALP) following the manufacturer's instructions (Beyotime, Shanghai, China). For alizarin red staining, cells were treated according to the experimental design. After 14 days, Cells were fixed and added with Alizarin Red-S solution (Beyotime) for 30 min. Then mineralized nodules were photographed. Cultured cells were seeded in 12-well plates and treated with FAC and E 2 . After 10 days, cells were lysed with cell lysis buffer and centrifuged at 250 g for 5 min. Aliquots of supernatant were collected to measure ALP activity and protein concentration by using an ALP kit (Jiancheng, Nanjing, China) and a BCA protein assay kit (Beyotime) respectively. The OD was measured at a wavelength of 520 nm by using the BioTek microplate reader.
Tartrate-resistant acid phosphatase staining
To estimate the number of differentiated osteoclasts from bone marrow and RAW264.7 cells, they were stained with tartrate-resistant acid phosphatase (TRAP). Briefly, cells were fixed in 3.7% formaldehyde for 10 min and then incubated for 60 min at 37 8C in the dark with a solution containing sodium nitrite, Fast Garnet GBC, acetate, naphthol AS-BI phosphoric acid, and tartrate from the Leukocyte Acid Phosphatase Assay kit (Sigma) following the manufacturer's instructions. Trap-positive multinucleated cells (MNCs) containing three or more nuclei were scored using light microscopy. The data are expressed as the meanGS.D. of three samples.
Resorption pit assay
RAW264.7 cells were detached from the flask by using a trypsin/EDTA solution and were then resuspended as a single cell suspension. Cells were re-plated in Osteo Assay Surface 24-well plates (Corning, Corning, NY, USA) at a density of 2.5!10 4 cells/well. a-MEM/10% FBS containing 100 ng/ml RANKL was added to each well. Plates were incubated at 37 8C in a humidified atmosphere of 5% CO 2 for 7 days. The serum-free medium was changed and reagents were added on day 4. The medium was aspirated from the wells on day 7 and 400 ml of 10% bleach solution was added for 5 min. The wells were washed twice in distilled water. Individual pits were examined in dry wells by using a light microscope. The number of pits and the object area/total area were measured using Image-Pro Plus version 6.0 Software (Media Cybernetics, Warrendale, PA, USA).
Measurement of intracellular ROS level
OB and RAW264.7 cells were cultured and treated in 96-well plates. On the last day of culture, cells were incubated in the dark at 37 8C in serum-free medium containing 10 mM DCFH-DA (Beyotime) for 20 min. The cells were washed three times in serum-free medium to remove extracellular DCFH-DA. Cells were immediately examined using a fluorescent microscope. The OD was measured using a multi-detection reader at excitation and emission wavelengths of 488 and 525 nm respectively.
Micro-computed tomography analysis
The distal region of the left femur was subjected to threedimensional micro-computed tomography (micro-CT) analysis. Bones were analyzed on a SkyScan 1172 highresolution micro-CT scanner (SkyScan, Aartselaar, Belgium) using a 9-mm voxel size, 59 KVp, 127 mA, and 0.48 rotation step. The measured volumes of the cortical and trabecular regions of interest (ROIs) were obtained using a utility of the processing system. Trabecular ROIs extended from 50 mm proximally to the end of the distal growth plate over 1.7 mm toward the diaphysis. Cortical ROIs were 1.7 mm segments of the femoral middle-diaphysis. Cortical ROIs were defined by digitally subtracting the respective trabecular ROIs from the whole bone volume. All ROIs were drawn semiautomatically. Bone mineral density measurements were performed on cortical and trabecular volumes after segmentation of the bone voxels by using the global threshold, including only bone slices. Cone-beam CT Reconstruction Software version 2.6 was used to perform three-dimensional reconstructions and data analyses. The following trabecular and cortical parameters were analyzed: bone volume/total volume (BV/TV), trabecular number (Tb.N), trabecular separation (Tb.Sp), trabecular thickness (Tb.Th), trabecular bone pattern factor (Tb.Pf), structure model index (SMI), cortical volume, cortical surface, and cortical thickness.
Quantitative RT-PCR analysis
Total RNA was extracted from OB and RAW264.7 cells and was reverse-transcribed into cDNA by using a reverse transcription kit (Invitrogen) following the manufacturer's instructions. The cDNA was mixed with SYBR Green Supermix (Bio-Rad) and primers for runt-related transcription factor 2 (RUNX2),transcription factor 7 (SP7), bone g-carboxyglutamate protein (BGLAP), TRAP5, cathepsin k (CTSK), matrix metallopeptidase 9 (MMP9), or calcitonin receptor (CALCR) respectively. The primers used are listed in Table 1 . Each experiment was performed in duplicate and the results were standardized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). All primers were purchased from Sangon (Shanghai, China). Data are expressed as the fold-change relative to the control.
Measurement of ferritin, oxidative stress, and markers of bone turnover in serum Serum ferritin was measured using a mouse ferritin ELISA kit (Abnova, Taipei, China) according to the manufacturer's protocol. Bone turnover markers including ALP, osteocalcin, C-terminal telopeptide of type 1 collagen (CTX), and TRAP5b were analyzed. ELISA kits for osteocalcin, CTX, and Trap5b were purchased from R&D, while the ALP kit has been previously described. Absorbance at 450 nm was measured for the contents of each well. 
BGLAP, bone g-gamma carboxyglutamate protein; CALCR, calcitonin receptor; CTSK, Cathepsin K; MMP9, matrix metallopeptidase 9; RT-PCR, real-time polymerase chain reaction; RUNX2, runt-related transcription factor 2, SP7, transcription factor SP7; TRAP5, tartrate-resistant acid phosphatase.
The plate reader was calibrated according to the manufacturer's specifications. Oxidative stress markers, including malondialdehyde (MDA) and superoxide dismutase (SOD), were detected in the serum by using the MDA assay kit and SOD activity assay kit respectively. ROS will alter the level of SOD and MDA (Hohn et al. 2013) . Both of the kits were purchased from Jiancheng. The ODs of MDA and SOD were measured at wavelengths of 532 and 450 nm respectively.
Western blot analysis
To analyze the level of NF-kB, whole-cell, cytoplasmic, and nuclear proteins were extracted. Nuclear proteins were extracted using the NucBuster Protein Extraction kit (Novagen, Rockland, MA, USA). Briefly, 2!10 7 RAW264.7 cells were lysed with 150 ml of reagent 1 to remove cytoplasmic proteins. The pellet was resuspended in 1 ml of 100! Protease Inhibitor Cocktail, 1 ml of 100 mM DTT, and 75 ml of reagent 2. The nuclear protein extracts were collected using centrifugation at 16 000 g for 5 min at 4 8C. A total of 40 mg of protein was mixed with 5!SDS-PAGE Sample loading buffer (Beyotime), boiled at 100 8C for 5 min. Proteins were transferred to PVDF membranes by electroblotting. The membranes were blocked using 5% non-fat dry milk in TBST for 1.5 h and then probed with anti-P50 (1:5000, Millipore, Billerica, MA, USA), anti-P65 (1:2000, Millipore), anti-IkBa (1:1000, Cell Signaling Technology, Danvers, MA, USA), anti-PIkBa (1:1000, Cell Signaling Technology), anti-histone 3 (1:5000, Millipore). Primary antibodies were detected using the DyLing TM800 Labeled Antibody to Rabbit/Mouse IgG (HtL) (1:10 000, KPL, Gaithersburg, MD, USA). Bound complexes were measured using the Odyssey Infrared Imaging System.
Statistical analysis
All the results are presented as the meanGS.D. The differences between the experimental groups were evaluated using one-way ANOVA followed by Bonferroni post tests to allow for multiple comparisons. Statistical analyses were performed using the SPSS 19.0 Software. P!0.05 was considered statistically significant.
Results
Osteopenia in mice is associated with iron accumulation and estrogen deficiency
As shown in Fig. 1A , ovariectomized mice fed the control diet showed little weight increase during the period of the experiment. FAC treatment (1.2 g/kg per week) over a 2-month period resulted in a marked iron accumulation in the liver, the largest ferritin reservoir. We stained the liver and bone sections by using Prussian blue, which indicated that iron was deposited in both the liver and bone marrow (Fig. 1B and C) . Serum ferritin, a classic marker of iron storage, appeared to be significantly different between these groups (FZ142.87, P!0.001). Ferritin increased in the F (335.30G44.10 mg/l) and FCOVX (324.80G 38.60 mg/l) groups compared with the Con (39.40G 3.81 mg/l) and OVX (41.38G5.56 mg/l) groups (P!0.001, P!0.001) (Fig. 1D) .
To evaluate the effects of E 2 and FAC on bone metabolism, micro-CT analyses of trabecular and cortical bone were performed. As expected, the excess iron in the FCOVX group (absence of estrogen) markedly reduced both trabecular and cortical bone compared with the OVX group, whereas the Con and F groups (presence of estrogen) showed no significant difference in these parameters except Tb.Sp (Table 2) . No significant differences were observed for the Tb.N, SMI, and cortical indexes. These data indicated that estrogen played a key role in suppressing iron-induced bone loss. Three-dimensional reconstruction images are shown in Fig. 2A .
Oxidative stress was evaluated by measuring the levels of MDA and SOD, two commonly used indicators of ROS levels. We compared MDA and SOD in ovariectomized and sham-operated mice that had been administered FAC and normal saline. Differences were significant (MDA: FZ19.62, P!0.001; SOD: FZ22.73, P!0.001). FAC was shown to promote the generation of ROS in ovariectomized mice (MDA: 8.46G1.91 versus 16.14G2.42 nM, PZ0.004; SOD: 4.43G0.81 versus 1.80G0.67 U/m, P!0.001, OVX versus FCOVX), whereas the presence of estrogen suppressed oxidative stress (MDA: 6.22G1.38 versus 8.14G2.06 nM, PZ0.182; SOD: 5.83G0.77 versus 4.73G0.93 U/ml, PZ0.081, Con versus F) (Fig. 2B and C) .
To further investigate bone turnover, sera were analyzed using ELISA kits. The levels of two factors involved in bone resorption, TRAP5b and CTX, were significantly different (TRAP5b: FZ140.08, P!0.001; CTX: FZ266.93, P!0.001). We observed higher levels of TRAP5b and CTX in the FCOVX group than in the OVX group (TRAP5b: 60.15G3.49 versus 79.04G6.47 U/l, P!0.001; CTX: 9624G 1140 versus 14506G915 pmol/l, P!0.001,OVX versus FC OVX). However, the presence of estrogen abrogated this effect. In accordance with the results of the micro-CT analysis, no significant differences were observed between the Con and F groups (TRAP5b: 23.27G5.66 versus 29.51G5.65 U/l, PZ0.085; CTX: 2588G662 versus 3633G 449 pmol/l, PZ0.065, Con versus F) ( Fig. 2D and E) . We also assessed ALP and osteocalcin levels in each group (ALP: FZ30.69, P!0.001; osteocalcin: FZ69.93, P!0.001). Iron reduced ALP and osteocalcin in both ovariectomized (ALP: 17.57G2.09 versus 11.65G2.02 U/100 ml, P!0.001; osteocalcin: 98.27G7.00 versus 83.06G4.46 ng/ml, PZ0.002, OVX versus FCOVX) and sham-operated (ALP: 14.15G1.22 versus 8.47G1.30 U/100 ml, P!0.001; osteocalcin: 73.33G 3.85 versus 57.75G3.95 ng/ml, P!0.001, Con versus F) mice, indicating that estrogen improved iron-induced osteopenia during the process of bone resorption, but not during bone formation (Fig. 2F and G) .
Iron-induced defects in bone formation were not attenuated by estrogen
We investigated activation of varieties of deionized-watertreated and FAC-treated OBs in the presence of E 2 or vehicle. medium containing E 2 . In comparison with the cells treated with E 2 alone, the cells co-incubated in FAC and E 2 had lower ALP activity (1.49G0.20 versus 0.76G 0.20 U/gprot, E 2 -treated versus FAC&E 2 -treated, PZ0.021) (Fig. 3A and B) . Alizarin red staining provided us with a result that FAC inhibited OBs mineralization ability with or without estrogen. (Fig. 3C) Quantitative RT-PCR analysis of RUNX2, SP7, and BGLAP mRNA levels confirmed the ALP analysis results, demonstrating that iron-induced changes in mRNA levels were not attenuated by E 2 (RUNX2: FZ9.21, PZ0.029, SP7: FZ15.56, PZ0.011; BGLAP: FZ7.20, PZ0.043). FAC decreased RUNX2, SP7, and BGLAP expression, and the fold-decreases of these mRNAs, 0.24-, 0.69-and 0.72-fold (PZ0.036, 0.481, 0.049 respectively), were significantly different from that of the deionized water control. When E 2 was added to the wells, the FAC-induced fold-changes decreased to 0.52-, 0.66-and 0.35-fold (PZ0.020, 0.292, 0.050 respectively) (Fig. 3D, E and F) . Therefore, our quantitative RT-PCR analysis generated data that were consistent with that from the animal experiments. Next, we determined the levels of ROS in each group. Because cellular ROS reportedly decreases in response to E 2 and promotes apoptosis of OBs, we investigated whether FAC could influence oxidative stress in the presence and absence of E 2 . The cultures were treated and the production rate of ROS was then assessed using the fluorescent probe DCFH-DA. As shown in Fig. 3G and H, the production rate of ROS was significantly different (FZ37.44, P!0.001). ROS increased significantly in response to 10-mM FAC treatment (100.00G10.36 versus 156.30G24.57%, deionized water-treated versus FAC-treated, P!0.001), but this effect was attenuated in cells that were pretreated in 10 nM E 2 (54.16G14.90 vs 76.06G19.09%, E 2 -treated versus FAC&E 2 -treated, PZ0.142). These data supported the conclusions of the in vivo experiments. However, they varied from the results of the quantitative RT-PCR analysis of OBs. Briefly speaking, though E 2 attenuated the ironinduced ROS level, iron-induced reduction in activation of OBs could not be improved by E 2 .
Inhibitory effect of estrogen on osteoclast differentiation in the presence of iron
Because the iron-induced defects in bone formation could not be attenuated by estrogen, we next explored the combined actions of estrogen and iron on bone resorption by evaluating the effects of FAC and E 2 on osteoclast activation. Various concentrations of FAC (0, 12, 25, 50, 100, and 200 mM) and E 2 (0, 1, 10, 10 2 , 10 3 , and 10 4 nM) were applied to RAW264.7 cells in the presence of 100 ng/ml of RANKL. As indicated by the number of Trap-positive MNCs, though higher concentrations of FAC and E 2 inhibited proliferation of the cells (Fig. 4A and B) , differentiation of RAW264.7 cells was stimulated with the indicated doses of FAC (50 mM) (P!0.001) and inhibited with the indicated doses of E 2 (10 nM) (PZ0.001) (Fig. 4C and D) . These doses were used during the subsequent experiments. The number of Trap-positive MNCs in cultures treated with both FAC and E 2 was also scored (FZ43.19, P!0.001). Preliminary results indicated that FAC could only promote osteoclast differentiation in the absence of (Fig. 5A and B) , a finding consistent with the results of our resorption pit assay, including number of pits (FZ316.50, P!0.001) and area ratio (FZ61.13, P!0.001) (Fig. 5C , D and E). BMMs isolated from femurs were cultured and then Trap stained. The number of Trap-positive MNCs was significantly different between the four groups (FZ92.24, P!0.001). The number for the FCOVX group was significantly greater than that for the OVX group (12.67G1.75 versus 19.67G3.08, OVX versus FCOVX, P!0.001). However, the presence of estrogen partly abrogated iron-induced osteoclast differentiation (2.33G 1.75 versus 3.17G1.47, Con versus F, PZ0.501) ( Fig. 5F and G). This result supports our hypothesis that estrogen ameliorates iron-induced bone loss during the process of bone resorption, but not bone formation. We used the fluorescent probe DCFH-DA to determine whether iron or estrogen changed intracellular ROS levels. As expected, the results of this experiment were consistent with the results for detection of ROS in OBs, as shown in Fig. 6A and B (FZ55.66, P!0.001). We examined whether iron and estrogen affected osteoclast differentiation by measuring TRAP, CTSK, MMP9, and CALCR expression. As shown in Fig. 6C, D , E and F (TRAP: FZ7.12, PZ0.044, CTSK: FZ9.92, PZ0.025; MMP9: FZ16.00, PZ0.011, CALCR: FZ13.50, PZ0 .015), the expression levels in iron-treated cells were significantly higher than in cells treated with deionized water, increasing by 2. respectively (PZ0.047, 0.036, 0.046, !0.001 respectively) . Unexpectedly, compared with cells treated with estrogen alone, the expression of TRAP, CTSK, MMP9, and CALCR displayed no obvious differences in the cells treated with estrogen and iron (1.27-, 2.06-, 2.24-, and 3.68-fold respectively) (PZ0.741, 0.274, 0.386, 0.201 respectively) . To further elucidate this mechanism, we extracted nuclear and cytoplasmic proteins and performed a western blot analysis. Nuclear proteins P65 and P50 and cytoplasmic proteins IkBa and phosphorylated IkBa were examined (FZ59.52, 41.81, 38.92, 78 .21, respectively; P!0.001, !0.001, !0.001, !0.001 respectively). No significant change of P65, P50, IkBa and PIkBa activation was observed if cells were treated with E 2 (PZ0.091, 0.109, 0.258, 0.149 respectively). Whereas IkBa, phosphorylated IkBa, P65, and P50 were obviously affected by iron in the absence of E 2 (PZ0.001, !0.001, !0.001, 0.007 respectively) ( Fig. 6G and H) .
Discussion
Postmenopausal osteoporosis, which is characterized by decreased bone mass and microarchitectural deterioration of bone tissue, represents an increasing medical and socioeconomic threat in the aged population worldwide. In addition to estrogen deficiency, iron accumulation has recently been reported to be a secondary causative factor involved in PMO (Jia et al. 2012 , He et al. 2013 , Kim et al. 2013 . Postmenopausal women with abnormally high iron are reportedly more susceptible to osteoporosis (Kim et al. 2012 (Kim et al. , 2013 . However, whether iron accumulation affects bone metabolism in premenopausal women has not, to our knowledge, been examined. This prompted us to ask whether an excess of iron leads to bone loss in the presence of estrogen. In this study, we generated an OVX mouse model with elevated iron to replicate the characteristic of postmenopausal females. Body weight had an influence on bone mass. The ratio of weight gain in OVX mice was slowed down with a control diet. Our mouse model had a pronounced bone phenotype, with defects similar to the OVX mouse model with normal levels of iron. Defects included trabecular and cortical thinning and alterations in the material properties of the bones. Considering the individual differences between mice and the tiny amounts of samples, levels of Tb.Sp in F group were increased and no significant difference was observed in Tb.N, SMI, cortical volume, surface, or thickness. In spite of these results, changes of other parameters were in accordance with theoretical analysis. In addition, a significant decrease in bone formation and resorption activities were observed in our model, recapitulating iron-induced osteopenia in ovariectomized mice. Similar results have been reported by Jia et al. (2012) and Tsay et al. (2010) .
We also established an iron-accumulation mouse model that was not ovariectomized. In contrast to our OVX model, these mice experienced minimal bone loss, indicating a central role for the bioavailability of estrogen in attenuating iron-induced bone turnover. Interestingly, serum levels of bone formation markers were not consistent with the results of the micro-CT analysis, while those of bone resorption markers were consistent. Based on these findings, we investigated whether estrogen played a key role in protecting OB activity or affecting osteoclast differentiation in vitro. Expression of RUNX2 and SP7 decreased in iron-treated OBs in both the presence and absence of estrogen. In order to determine the dose of FAC and E 2 , we generated dose-response curves before performing experiments on osteoclasts. We found that FAC affected differentiation of osteoclasts at a concentration of 50 mM. The concentration for E 2 was 10 nM. We also found that the differentiation of BMMs and RAW264.7 cells could not be stimulated using FAC when estrogen was present. Therefore, we proposed the hypothesis that estrogen protected mice from iron-induced osteopenia by influencing osteoclast differentiation, but not OB activity.
Estrogen is the predominant female steroid hormone and a pivotal regulator in bone formation and bone resorption processes (Chokalingam et al. 2012) . 
